Lumachi, F., et al., Treatment of estrogen receptor-positive breast cancer. Curr Med Chem, 2013. 20(5): p. 596-604.F. Lumachi, A. Brunello, M. Maruzzo, U. Basso, S.M. Basso, Treatment of es- trogen receptor-positive breast cancer, Curr. Med. Chem. 20 (5) (2013) 596e604...
Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 216-230.W. Zwart, V. Theodorou, and J. S. Carroll, "Estrogen receptor- positive breast cancer: a multidisciplinary challenge," Wiley Interdisciplinary Reviews. Systems Biology and ...
ObservationsBreast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerlyHER2): hormone receptor positive/ERBB2negative (70% of patients),ERBB2positive (15%-20%),...
6 reagents referenced in Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive AssaysEstrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century...
Here, we retrospectively evaluated the importance of HER4 expression on the outcome of tamoxifen- and aromatase inhibitor-treated estrogen receptor-positive breast cancer patients (n = 258). In addition, we experimentally analyzed the efficiency of tamoxifen treatment as a function of HER4 co-expr...
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adop
The new data suggested that women with ER-positive breast cancer should at least consider taking anti-estrogen therapy beyond five years, the researchers said. Doctors have long known that five years of tamoxifen reduces recurrence by approximately half during treatment, and by nearly a third over...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
Stage 0 is ductal carcinoma in situ, which is noninvasive but progresses to invasive cancer in up to 40% of patients. Ductal carcinoma in situ is treated with lumpectomy and radiation or with mastectomy. If ductal carcinoma in situ is estrogen receptor-positive, patients may also receive ...